BRDTP1

Across TCGA pan-cancer cohorts, BRDTP1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BRDTP1 data layer compared with 12 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BRDTP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BRDTP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and BLCA are the cancer types where BRDTP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.411	0.753	<.001	66	view →
UCEC	DFS	Median	All	1.000	0.632	.011	34	view →
BLCA	DFS	Median	III,IV	0.083	0.572	<.001	12	view →
COAD	OS	Median	All	0.556	0.870	.024	12	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
SKCM	OS	Median	IV	0.179	0.755	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BRDTP1–HNSC (OS)

Open the HNSC breakdown →